WallStSmart
NTLA

Intellia Therapeutics Inc

NASDAQ: NTLA · HEALTHCARE · BIOTECHNOLOGY

$14.42
-8.20% today

Updated 2026-06-05

Market cap
$1.92B
P/E ratio
P/S ratio
29.02x
EPS (TTM)
$-3.52
Dividend yield
52W range
$7 – $28
Volume
6.2M

Intellia Therapeutics Inc (NTLA) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item201420152016201720182019202020212022202320242025
Total assets$10.69M$82.14M$298.97M$376.24M$347.31M$334.28M$676.32M$1.29B$1.52B$1.30B$1.19B$842.13M
Cash & equivalents$9.85M$75.82M$273.06M$340.68M$58.86M$57.23M$160.02M$123.41M$523.51M$226.75M$189.18M$155.46M
Current assets$10.13M$77.63M$281.31M$354.83M$324.98M$289.48M$616.52M$769.30M$1.22B$998.33M$639.86M$527.71M
Total liabilities$3.13M$14.78M$89.13M$75.64M$69.39M$64.40M$149.25M$254.22M$284.53M$250.81M$319.06M$170.73M
Current liabilities$2.35M$10.70M$30.73M$31.36M$40.57M$35.63M$64.25M$125.83M$126.55M$115.21M$110.85M$103.88M
Long-term debt$0.00$0.00
Shareholder equity$7.57M$67.36M$209.84M$300.60M$277.92M$269.88M$527.07M$1.04B$1.24B$1.05B$871.96M$671.39M
Retained earnings$-9.54M$-21.94M$-53.57M$-121.11M$-201.03M$-300.88M$-435.11M$-703.00M$-1.18B$-1.66B$-2.18B$-2.59B
Accounts receivable$1.00M$6.45M$10.47M$7.55M$4.62M$2.13M$2.03M$3.77M$36.46M$8.52M$9.47M
Inventory$1.00$1.00$1.00$1.00$-19.15M$-337.36M$-69.34M
Goodwill$0.00$0.00

Frequently asked questions

What is Intellia Therapeutics Inc's revenue?

Intellia Therapeutics Inc's trailing twelve-month revenue is $66.09M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is NTLA?

In its most recent fiscal year, NTLA ran a gross margin of 76.47%, an operating margin of -651.67%, and a net margin of -609.85%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does NTLA generate?

NTLA produced $-354.66M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NTLA's balance sheet healthy?

NTLA holds $155.46M in cash and equivalents against — in long-term debt, on $671.39M of shareholder equity. That debt is best read against the cash flow the business throws off each year.